Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interference with pathways activated by topoisomerase inhibition alters the surface expression of PD‑L1 and MHC I in colon cancer cells

9 Dec 2022

Abstract excerpt

Topoisomerase inhibitors are clinically used to treat various cancer types, including colorectal cancer. These drugs also activate signaling pathways that modulate cell survival and immune cell functions. Immunotherapy is promising for certain tumors, including microsatellite instable colorectal cancer, but not for microsatellite stable colorectal cancer. The reasons for this lack of responsiveness are largely...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Colorectal Cancer Treatments and Studies
Share to Immune Cell Function and Interaction

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36589674
DOI: 10.3892/ol.2022.13628

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Interference with pathways activated by topoisomerase inhibition alters the surface expression of PD‑L1 and MHC I in colon cancer cellsPMID 36589674Read ↗

The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints.Semantic proximity Read ↗

Clinical and Cellular Roles for TDP1 and TOP1 in Modulating Colorectal Cancer Response to IrinotecanSemantic proximity Read ↗

Increased topoisomerase IIα expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosisSemantic proximity Read ↗

Proteasome inhibitors restore the STAT1 pathway and enhance the expression of MHC class I on human colon cancer cellsSemantic proximity Read ↗

PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes.Semantic proximity Read ↗

Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targetsSemantic proximity Read ↗

Preclinical efficacy of carfilzomib in BRAF-mutant colorectal cancer models.Semantic proximity Read ↗

DNA Repair and Resistance to Topoisomerase I Inhibitors: Mechanisms, Biomarkers and Therapeutic TargetsSemantic proximity Read ↗

In Vivo Topoisomerase I Inhibition Attenuates the Expression of Hypoxia-Inducible Factor 1α Target Genes and Decreases Tumor AngiogenesisSemantic proximity Read ↗

Topoisomerase I-DNA covalent complexes in human colorectal cancer xenografts with different p53 and microsatellite instability status: relation with their sensitivity to CTP-11.Semantic proximity Read ↗

Protein Kinase D as a Potential Chemotherapeutic Target for Colorectal CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.